|
|
 Previous Article | Table of Contents | Next Article 
In vivo hematopoietic effects of recombinant interleukin-1 alpha in mice:
stimulation of granulocytic, monocytic, megakaryocytic, and early erythroid
progenitors, suppression of late-stage erythropoiesis, and reversal of
erythroid suppression with erythropoietin
CS Johnson, DJ Keckler, MI Topper, PG Braunschweiger and P Furmanski
Laboratory of Experimental Hematology, AMC Cancer Research Center, Denver,
CO 80214.
Interleukin-1 alpha (IL-1 alpha) is a macrophage-derived, multifunctional
cytokine that broadly potentiates myelopoiesis and induces the synthesis of
hematopoietic colony-stimulating factors (CSF) in vitro and in vivo. To
evaluate the possibility for use of IL-1 alpha in ameliorating in vivo bone
marrow suppression induced by drugs or radiation, we examined the in vivo
effects of the cytokine on erythropoietic and other hematopoietic
progenitor cells. Normal mice were treated with a single intraperitoneal
(IP) injection of recombinant human IL-1 alpha at varying doses and were
assayed at various times post-treatment. By six hours postinjection, a
significant suppression of mature erythroid progenitors (CFU-E) was
observed in animals treated with IL-1 alpha (0.5 micrograms/mouse), with
maximum suppression of CFU-E and peripheral blood reticulocyte counts
occurring at 24 hours. Decreases in peripheral blood hematocrit did not
occur after a single IL-1 alpha injection but were observed after multiple
injections of the cytokine. The suppressive effects of IL-1 alpha on
late-stage erythropoiesis were abrogated by simultaneous administration of
erythropoietin (EPO). At 48 hours post-treatment, a marked stimulation was
observed in the numbers of spleen and marrow immature erythroid (BFU-E),
macrophage (CFU-M), granulocyte (CFU-G), granulocyte- macrophage (CFU-GM),
and megakaryocyte (CFU-meg) progenitor cells. These results demonstrate the
potential use of IL-1 alpha as a generalized stimulator of hematopoiesis
and show that the cytokine- induced suppression of late-stage
erythropoiesis can be prevented by EPO.
Volume 73,
Issue 3,
pp. 678-683,
02/15/1989
Copyright © 1989 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. W. Adamson
The Anemia of Inflammation/Malignancy: Mechanisms and Management
Hematology,
January 1, 2008;
2008(1):
159 - 165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Raghavan and P. E. Marik
Anemia, Allogenic Blood Transfusion, and Immunomodulation in the Critically Ill
Chest,
January 1, 2005;
127(1):
295 - 307.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tsantes, S. Tassiopoulos, S. I. Papadhimitriou, S. Bonovas, L. Kavalierou, G. Vaiopoulos, and I. Meletis
Suboptimal Erythropoietic Response to Hypoxemia in Idiopathic Pulmonary Fibrosis
Chest,
August 1, 2003;
124(2):
548 - 553.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E Barr and M. F Barbe
Pathophysiological Tissue Changes Associated With Repetitive Movement: A Review of the Evidence
Physical Therapy,
February 1, 2002;
82(2):
173 - 187.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Corazza, Y. Beguin, P. Bergmann, M. Andre, A. Ferster, C. Devalck, P. Fondu, M. Buyse, and E. Sariban
Anemia in Children With Cancer Is Associated With Decreased Erythropoietic Activity and Not With Inadequate Erythropoietin Production
Blood,
September 1, 1998;
92(5):
1793 - 1798.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
